Debates in Nephrology

318 Should Buttonhole Cannulation of Arteriovenous Fistulas be Used? PRO
Laura Labriola
See related commentary on page 326 and debates on page 322.

322 Should Buttonhole Cannulation of Arteriovenous Fistulas Be Used? CON
Jennifer M. MacRae
See related commentary on page 326 and debates on page 318.

Moderator Commentary

326 Should Buttonhole Cannulation of Arteriovenous Fistulas Be Used? Moderator Commentary
Anil K. Agarwal
See related debates on pages 318 and 322.

Original Investigations

Acid/Base and Electrolyte Disorders

330 Influence of Medications Containing Acid Salts on Serum Bicarbonate in CKD
John Gardner, Kunani Tuttle, and Kalani L. Raphael

Acute Kidney Injury and ICU Nephrology

337 Serum Transaminases at Presentation and Association with Acute Dialysis in Children with Hemolytic Uremic Syndrome
Saurabh Talathi, Margaux Barnes, Inmaculada Aban, Reed Dimmitt, and David J. Askenazi

343 \( \alpha_1 \)-Acid Glycoprotein Attenuates Adriamycin-Induced Nephropathy via CD163 Expressing Macrophage Induction
Rui Fujimura, Hiroshi Watanabe, Kento Nishida, Yukio Fujiwara, Tomoaki Koga, Jing Bi, Tadashi Imafuku, Kazuki Kobayashi, Hisakazu Komori, Masako Miyahisa, Hitoshi Maeda, Motoko Tanaka, Kazutaka Matsushita, Takashi Wada, Masafumi Fukagawa, and Toru Maruyama

Dialysis

354 Utility of Peritoneal Scintigraphy in Peritoneal Dialysis Patients: One Center Experience
R. Haridian Sosa Barrios, María Eugenia Rioja Martín, Víctor Burguera Vion, Astrid Lucía Santos Carreño, Milagros Fernández Lucas, and Maite E. Rivera Gorrín

Glomerular and Tubulointerstitial Diseases

359 Clinical Response and Pattern of B cell Suppression with Single Low Dose Rituximab in Nephrology
Jacob George, Sunu Alex, E.T. Arun Thomas, Noble Gracious, Nalanda S. Vineetha, and Sajeev Kumar

Hypertension

368 Baseline Diastolic Blood Pressure and Cardiovascular Outcomes in SPRINT Participants with Chronic Kidney Disease
**Nephropharmacology**

376  **Anti-Cancer Activity of PAK4/NAMPT Inhibitor and Programmed Cell Death Protein-1 Antibody in Kidney Cancer**  

**Transplantation**

389  **Short-Term Immunopathological Changes Associated with Pulse Steroids/IVIG/Rituximab Therapy in Late Kidney Allograft Antibody Mediated Rejection**  

**Brief Communication**

399  **Use of Immune Checkpoint Inhibitors in End Stage Kidney Disease Patients, Single Center Experience and Review of the Literature**  
Jamie S. Hirsch, Rimda Wanchoo, Jia H. Ng, Yuriy Khanin, and Kenar D. Jhaveri

**Global Perspectives**

403  **Delivering Safe and Effective Hemodialysis in Patients with Suspected or Confirmed COVID-19 Infection: A Single-Center Perspective from Italy**  
Maurizio Gallieni, Gianmarco Sabiu, and Daniele Scorza

410  **Peritoneal Dialysis for Acute Kidney Injury Treatment in the United States: Brought to You by the COVID-19 Pandemic**  
Vesh Srivatana, Vikram Aggarwal, Fredric O. Finkelstein, Mihran Naljayan, John H. Crabtree, and Jeffrey Perl

416  **Global Dialysis Perspective: Japan**  
Norio Hanafusa and Masafumi Fukagawa

420  **The Role of Telemedicine in Kidney Transplantation: Opportunities and Challenges**  
Beatrice P. Concepcion and Rachel C. Forbes

**Perspective**

424  **ESKD Treatment Choices Model: Responsible Home Dialysis Growth Requires Systems Changes**  
Eric L. Wallace and Michael Allon

**Clinical Images in Nephrology and Dialysis**

428  **Green Effluent in a Patient on Continuous Veno-venous Hemodiafiltration**  
Priscila Dias Gonçalves, Geraldo Rubens Ramos de Freitas, and Thiago de Azevedo Reis

430  **Facial Deformity in a Patient with Chronic Secondary Hyperparathyroidism**  
Sebastiaan Dhont, Liesbeth Viaene, and Pieter Evenepoel

---

On the Cover  
RENCA tumors express both PD-L1 and PD-L2 and are highly proliferative. Subcutaneous RENCA tumors from untreated Balb/cJ mice were fixed, paraffin-embedded, sectioned and stained with hematoxylin and eosin or subjected to immunohistochemistry for Ki67, PD-L1 and PD-L2 using DAB as the chromagen and a hematoxylin counterstain. Adapted from Figure 2 of “Anti-Cancer Activity of PAK4/NAMPT Inhibitor and Programmed Cell Death Protein-1 Antibody in Kidney Cancer” by Josephine F. Trott, Omran Abu Aboud, Bridget McLaughlin, Katie L. Anderson, Jaime F. Modiano, Kyoungmi Kim, Kuang-Yu Jen, William Senapedis, Hua Chang, Yosef Landesman, Erkan Baloglu, Roberto Pili, and Robert H. Weiss. KIDNEY360 1: 376–388, 2020. doi: 10.34067/KID.0000282019.